Mitochondrial E3 ubiquitin ligase 1 (MUL1) as a novel therapeutic target for diseases associated with mitochondrial dysfunction

• Published in: IUBMB life Vol. 74; no. 9; pp. 850 - 865
• Main Authors: Calle, Ximena, Garrido‐Moreno, Valeria, Lopez‐Gallardo, Erik, Norambuena‐Soto, Ignacio, Martínez, Daniela, Peñaloza‐Otárola, Allan, Troncossi, Angelo, Guerrero‐Moncayo, Alejandra, Ortega, Angélica, Maracaja‐Coutinho, Vinicius, Parra, Valentina, Chiong, Mario, Lavandero, Sergio
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-09-2022; Wiley Subscription Services, Inc
• Subjects: Akt; AKT protein; and RNF218; Apoptosis; C1orf166; Cardiovascular diseases; Cell death; Cell fusion; Cell survival; Cytosol; FLJ12875; GIDE; Homeostasis; Immune response; Inflammation; MAPL; Membrane proteins; Mitochondria; mitochondria morphology; mitochondrial E3 ubiquitin ligase 1; MULAN; Neurological diseases; Organelles; p53 Protein; Proteins; Quality control; SUMO protein; Therapeutic targets; Tumor suppressor genes; Tumors; Ubiquitin; Ubiquitin-protein ligase; GIDE; C1orf166; MAPL; cell death; MULAN; inflammation; RNF218; Akt; FLJ12875; Mitochondrial E3 ubiquitin ligase 1; mitochondria morphology
• ISSN: 1521-6543; 1521-6551
• DOI: 10.1002/iub.2657

Mitochondrial E3 ubiquitin ligase 1 (MUL1) is a mitochondrial outer membrane‐anchored protein‐containing transmembrane domain in its N‐ and C‐terminal regions, where both are exposed to the cytosol. Interestingly the C‐terminal region has a RING finger domain responsible for its E3 ligase activity, as ubiquitin or in SUMOylation, interacting with proteins related to mitochondrial fusion and fission, cell survival, and tumor suppressor process, such as Akt. Therefore, MUL1 is involved in various cellular processes, such as mitochondrial dynamics, inter‐organelle communication, proliferation, mitophagy, immune response, inflammation and cell apoptosis. MUL1 is expressed at a higher basal level in the heart, immune system organs, and blood. Here, we discuss the role of MUL1 in mitochondrial dynamics and its function in various pathological models, both in vitro and in vivo. In this context, we describe the role of MUL1 in: (1) the inflammatory response, by regulating NF‐κB activity; (2) cancer, by promoting cell death and regulating exonuclear function of proteins, such as p53; (3) neurological diseases, by maintaining communication with other organelles and interacting with proteins to eliminate damaged organelles and; (4) cardiovascular diseases, by maintaining mitochondrial fusion/fission homeostasis. In this review, we summarize the latest advances in the physiological and pathological functions of MUL1. We also describe the different substrates of MUL1, acting as a positive or negative regulator in various pathologies associated with mitochondrial dysfunction. In conclusion, MUL1 could be a potential key target for the development of therapies that focus on ensuring the functionality of the mitochondrial network and, furthermore, the quality control of intracellular components by synchronously modulating the activity of different cellular mechanisms involved in the aforementioned pathologies. This, in turn, will guide the development of targeted therapies.